OpenAI收购Orchestra Bio布局AI制药与临床试验Agent
Many people are asking how to invest in AI and data centers. Here's a very good…
Many people are asking how to invest in AI and data centers. Here's a very good example of where AI is headed:
许多人都在询问如何投资人工智能和数据中心。这里有一个很好的例子，展示了人工智能的发展方向：
OpenAI’s acquisition of Orchestra Bio adds agents that coordinate drug development, tracking how problems like a failed manufacturing batch could delay clinical trials. Paired with Rosalind, it shows toward a broader ambition: embedding AI across both scientific research and the operational work needed to bring medicines to patients.
OpenAI 收购 Orchestra Bio 后，获得了能够协调药物开发的智能体（agents），可以追踪诸如制造批次失败等问题可能导致的临床试验延误。结合 Rosalind，这展现了更宏大的愿景：将人工智能嵌入到科学研究以及将药物带给患者所需的运营工作中。
Drug research and disease cure are among the significant fields in which AI extends and will make tremendous progress. Anthropic published something similar today.
药物研发和疾病治愈是人工智能延伸并将取得巨大进展的重要领域之一。Anthropic 今天也发布了类似的内容。
更进一步：量化金融体系
看懂新闻只是起点——沿量化金融路径，把它变成能交付的工程能力